Loading...
Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice
We identified all patients with chronic lymphocytic leukemia at Mayo Clinic treated with ibrutinib outside the context of a clinical trial; timing and reasons for discontinuation were ascertained, as were symptoms, exam and radiographic findings, and laboratory changes following discontinuation. Of...
Na minha lista:
| Udgivet i: | Leuk Lymphoma |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6813846/ https://ncbi.nlm.nih.gov/pubmed/31014142 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2019.1602268 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|